Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric ravulizumab study in generalized myasthenia gravis
2022-501882-29-00Phase 3Authorised
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Primary endpoints: Ravulizumab pharmacokinetics and Serum free C5 pharmacodynamics. Planned start Jun 2023; status: authorised.
02
Drugs
ravulizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2022-501882-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501882-29-00.